cfDNA as a predictive marker for the prognosis of severe courses in patients with influenza-like symptoms with and without SARS-CoV-2 infections in General Practice: A prospective cohort study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024722

Enrollment

Registered

2021-03-10

Start date

2021-08-19

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J06.9 U07.1

Interventions

Group 1: Patients with flu-like symptoms with a SARS-CoV-2 infection. All Patients will have venous blood (22.4 ml) collected at 3 different time points to determine cfDNA concentrations from blood pl

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Presence of symptoms of a flu infection. Consent for blood draw, oropharyngeal or naso-pharyngeal swab for a rapid SARS-CoV-2 antigen test, subsequent PCR if necessary, and completion of a questionnaire.

Exclusion criteria

Exclusion criteria: Severe acute or chronic disease with known elevated cfDNA levels based on disease (including tumor disease, severe renal insufficiency, severe/moderate inflammation based on preexisting disease). Lack of German language skills

Design outcomes

Primary

Measure	Time frame
Levels of cfDNA in patients with flu-like symptoms with and without SARS-CoV-2 infection and changes in concentrations during the course of illness.	—

Secondary

Measure	Time frame
Correlation between cfDNA levels and laboratory and clinical parameters (e.g. hsCRP, ESR, differential blood count, temperature, oxygen saturation, respiratory rate, and accompanying symptoms)	—

Countries

Germany

Contacts

Public ContactDorothea Dehnen

Institut für Allgemeinmedizin des Universitätsklinikums Essen

dorothea.dehnen@uk-essen.de02017238025

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 12, 2026